{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:45:35Z","timestamp":1789170335290,"version":"build-2803163510"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI72265"],"award-info":[{"award-number":["AI72265"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL107151"],"award-info":[{"award-number":["HL107151"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.anai.2018.02.031","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T13:53:54Z","timestamp":1519739634000},"page":"150-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["The eosinophil"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-6009","authenticated-orcid":false,"given":"Bruce S.","family":"Bochner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.02.031_bib0010","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2222.2010.03484.x","article-title":"Eosinophils in health and disease: the LIAR hypothesis","volume":"40","author":"Lee","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2018.02.031_bib0015","series-title":"Eosinophils in Health and Disease","first-page":"13","article-title":"The evolutionary origins and presence of eosinophils in extant species","author":"McGarry","year":"2012"},{"key":"10.1016\/j.anai.2018.02.031_bib0020","series-title":"Eosinophils in Health and Disease","year":"2012"},{"key":"10.1016\/j.anai.2018.02.031_bib0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri3341","article-title":"Eosinophils: changing perspectives in health and disease","volume":"13","author":"Rosenberg","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0030","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1182\/blood-2012-06-330845","article-title":"The expanding role(s) of eosinophils in health and disease","volume":"120","author":"Jacobsen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.anai.2018.02.031_bib0035","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.12688\/f1000research.11133.1","article-title":"Recent advances in understanding eosinophil biology","volume":"6","author":"Klion","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.anai.2018.02.031_bib0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jaci.2017.09.022","article-title":"Eosinophils and eosinophil-associated diseases: an update","volume":"141","author":"O'Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/asheducation-2015.1.92","article-title":"Eosinophilia: a pragmatic approach to diagnosis and treatment","volume":"2015","author":"Klion","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.anai.2018.02.031_bib0050","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.anai.2018.02.031_bib0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaip.2015.01.013","article-title":"Biologic therapies targeting eosinophils: current status and future prospects","volume":"3","author":"Legrand","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.02.031_bib0060","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1146\/annurev-pharmtox-010814-124407","article-title":"Novel targeted therapies for eosinophil-associated diseases and allergy","volume":"55","author":"Radonjic-Hoesli","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.anai.2018.02.031_bib0065","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.iac.2015.05.007","article-title":"Novel therapies for eosinophilic disorders","volume":"35","author":"Bochner","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.anai.2018.02.031_bib0070","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jaip.2017.08.001","article-title":"Biologic agents for the treatment of hypereosinophilic syndromes","volume":"5","author":"Kuang","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.02.031_bib0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fmed.2017.00115","article-title":"Transcription factors in eosinophil development and as therapeutic targets","volume":"4","author":"Fulkerson","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.anai.2018.02.031_bib0080","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.4049\/jimmunol.1600611","article-title":"IL-33 precedes IL-5 in regulating eosinophil commitment and is required for eosinophil homeostasis","volume":"197","author":"Johnston","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0085","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","article-title":"Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti\u2013IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0090","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1172\/JCI119789","article-title":"Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects","volume":"100","author":"Sehmi","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anai.2018.02.031_bib0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fmed.2017.00075","article-title":"Eosinophil activation status in separate compartments and association with asthma","volume":"4","author":"Johansson","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.anai.2018.02.031_bib0100","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaci.2007.03.048","article-title":"Eosinophil trafficking in allergy and asthma","volume":"119","author":"Rosenberg","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0105","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1182\/blood-2012-07-443424","article-title":"Use of 111-indium\u2013labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects","volume":"120","author":"Farahi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.anai.2018.02.031_bib0110","series-title":"Eosinophils in Health and Disease","first-page":"131","article-title":"6.3. Eosinophil trafficking","author":"Matsumoto","year":"2012"},{"key":"10.1016\/j.anai.2018.02.031_bib0115","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1182\/blood-2015-04-640623","article-title":"Mechanism of enhanced eosinophil survival in inflammation","volume":"125","author":"Zimmermann","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.anai.2018.02.031_bib0120","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0125","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/all.12169","article-title":"The consequences of not having eosinophils","volume":"68","author":"Gleich","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.02.031_bib0130","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1084\/jem.20020656","article-title":"Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo","volume":"195","author":"Yu","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.anai.2018.02.031_bib0135","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1126\/science.1100283","article-title":"A critical role for eosinophils in allergic airways remodeling","volume":"305","author":"Humbles","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.anai.2018.02.031_bib0140","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1126\/science.1099472","article-title":"Defining a link with asthma in mice congenitally deficient in eosinophils","volume":"305","author":"Lee","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.anai.2018.02.031_bib0145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12026-008-8058-5","article-title":"Eosinophils and their interactions with respiratory virus pathogens","volume":"43","author":"Rosenberg","year":"2009","journal-title":"Immunol Res"},{"key":"10.1016\/j.anai.2018.02.031_bib0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fmed.2017.00101","article-title":"Homeostatic eosinophils: characteristics and functions","volume":"4","author":"Marichal","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.anai.2018.02.031_bib0155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-065X.2011.01026.x","article-title":"Eosinophils: multifaceted biological properties and roles in health and disease","volume":"242","author":"Kita","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.anai.2018.02.031_bib0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00441-010-1049-6","article-title":"Eosinophils in innate immunity: an evolving story","volume":"343","author":"Shamri","year":"2011","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.anai.2018.02.031_bib0170","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cell.2013.02.053","article-title":"Type 2 innate signals stimulate fibro\/adipogenic progenitors to facilitate muscle regeneration","volume":"153","author":"Heredia","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.anai.2018.02.031_bib0175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1615\/CritRevImmunol.2016018726","article-title":"Eosinophils in homeostasis and their contrasting roles during inflammation and helminth infections","volume":"36","author":"Strandmark","year":"2016","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0180","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jaci.2012.07.024","article-title":"Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD)","volume":"130","author":"Bochner","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0185","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/ehm.11.81","article-title":"Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field","volume":"5","author":"Valent","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.anai.2018.02.031_bib0190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0195","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.031_bib0200","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.031_bib0205","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.iac.2007.06.003","article-title":"Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon","volume":"27","author":"Butterfield","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.anai.2018.02.031_bib0210","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0215","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0220","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the jak inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anai.2018.02.031_bib0225","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.it.2013.04.002","article-title":"Living and dying for inflammation: neutrophils, eosinophils, basophils","volume":"34","author":"Geering","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0230","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.02.031_bib0235","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti\u2013IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Menzies-Gow","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0240","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti\u2013interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2018.02.031_bib0245","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaci.2014.12.1871","article-title":"Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care","volume":"135","author":"Fajt","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0250","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.02.031_bib0255","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.031_bib0260","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.031_bib0265","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaip.2016.11.029","article-title":"Changing paradigms in the treatment of severe asthma: the role of biologic therapies","volume":"5","author":"Katial","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.02.031_bib0270","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI17974","article-title":"Anti\u2013IL-5 treatment reduces deposition of extracellular matrix proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics","volume":"112","author":"Flood-Page","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anai.2018.02.031_bib0275","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaip.2017.07.008","article-title":"New and anticipated therapies for severe asthma","volume":"5","author":"Peters","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.02.031_bib0280","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.02.031_bib0285","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0290","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.031_bib0295","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.anai.2018.02.031_bib0300","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.02.031_bib0305","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaci.2010.04.029","article-title":"Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis","volume":"126","author":"Conus","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.giec.2017.07.007","article-title":"Pharmacologic treatment of eosinophilic esophagitis: an update","volume":"28","author":"Schoepfer","year":"2018","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"10.1016\/j.anai.2018.02.031_bib0315","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2018.02.031_bib0320","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti\u2013IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0325","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcmd.2017.01.008","article-title":"The targeted eosinophil-lowering effects of dexpramipexole in clinical studies","volume":"63","author":"Dworetzky","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.anai.2018.02.031_bib0330","doi-asserted-by":"crossref","first-page":"AB64","DOI":"10.1016\/j.jaci.2016.12.256","article-title":"Dexpramipexole effectively lowers blood and tissue eosinophils in subjects with chronic rhinosinusitis with nasal polyps","volume":"139","author":"Prussin","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0335","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cea.12244","article-title":"Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial","volume":"44","author":"Neighbour","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2018.02.031_bib0340","doi-asserted-by":"crossref","first-page":"e007709","DOI":"10.1136\/bmjopen-2015-007709","article-title":"Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti\u2013GM-CSF antibody (KB003) in patients with inadequately controlled asthma","volume":"6","author":"Molfino","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.anai.2018.02.031_bib0345","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2018.02.031_bib0350","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.02.031_bib0355","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.031_bib0360","author":"Hirano","year":"2017"},{"key":"10.1016\/j.anai.2018.02.031_bib0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.031_bib0370","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the \u03b14\u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.anai.2018.02.031_bib0375","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jaci.2013.11.041","article-title":"The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders","volume":"133","author":"Legrand","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.031_bib0380","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/glycob\/cww024","article-title":"Siglec\u201dting the allergic response for therapeutic targeting","volume":"26","author":"Bochner","year":"2016","journal-title":"Glycobiology"},{"key":"10.1016\/j.anai.2018.02.031_bib0385","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2222.2011.03813.x","article-title":"A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma","volume":"42","author":"Barnes","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2018.02.031_bib0390","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/all.12096","article-title":"Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis","volume":"68","author":"Straumann","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.02.031_bib0395","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618301583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618301583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:20:46Z","timestamp":1761052846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120618301583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1081120618301583"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.02.031","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The eosinophil","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}